Testing HRS-1893 for heart failure with preserved ejection fraction
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 40 years old.
- You have been diagnosed with heart failure with preserved ejection fraction (your heart pumps normally but doesn't fill properly).
- Your heart failure symptoms are mild to moderate (NYHA class II or III).
- You do not have atrial fibrillation or a history of dangerous heart rhythms.
- You have not had a heart attack or major heart blockage in the last 6 months without treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This study tests a new drug called finerenone to see if it can improve heart function in people with a type of heart failure where the heart pumps normally but is stiff. It may help reduce symptoms and improve quality of life.
This is an early-stage safety study of an experimental drug called HRS-7156 in people with no serious health conditions. Researchers will monitor how your body tolerates the drug and how it moves through your system.
This trial tests an investigational drug called CK-4021586 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug is safe and well-tolerated. You may qualify if you are 40 to 85, have heart failure symptoms, and have a heart that pumps well but shows signs of strain.
This trial tests an oral drug called HRS-7535 for people with a certain type of heart failure (where the heart pumps normally but doesn't relax properly) and who also have obesity. It aims to see if the drug can improve symptoms and daily function.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.